Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
Generated Narrative: Evidence 236553
version: 65; Last updated: 2025-03-20 18:40:09+0000
Profile: ComparatorOnlyEvidence
RelatesTo
- type: part-of
- targetReference: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)
url: https://fevir.net/resources/Evidence/236553
identifier: FEvIR Object Identifier/https://fevir.net/FOI/236553, outcomeId/313880, picoId/85789, sectionId/73212
name: End_stage_kidney_disease_Comparator_Evidence_from_MAGICapp_313880
title: MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk
status: Active
publisher: Computable Publishing LLC
contact: support@computablepublishing.com
author: Computable Publishing®: MAGIC-to-FEvIR Converter:
| Code | Value[x] |
| Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence Communication | ComparatorOnlyEvidence |
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
description:
This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.
note: Defined as a GFR below 45 or a GFR below 70 AND macroalbuminuria (ACR > 200 mg/g); derived from RECODe (https://sanjaybasu.shinyapps.io/recode/).
variableDefinition
description:
Adults with type 2 diabetes with moderate CV risk -- Standard care
variableRole: Population
observed: Standard care Group in Adults with type 2 diabetes with moderate CV risk
variableDefinition
description:
End-stage kidney disease
variableRole: Outcome
observed: End-stage kidney disease
synthesisType: NOTSET
studyDesign: NO_STUDY
| Description | StatisticType | Quantity |
Risk 2.0% | Proportion | 0.02 |
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot2 based on FHIR 6.0.0-ballot2. Generated 2025-03-27
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change